Phosphonate Inhibitors Targeting HCV NS5b Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, primarily relying on interferon-α and ribavirin, are only 40% effective and have significant side effects, leading to a need for more effective and tolerable antiviral therapies.
Innovation Solution
Development of compounds with specific structures, such as those represented by Formulas I, II, III, or IV, which inhibit HCV NS5b polymerase, potentially used alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-α and ribavirin are used as standard treatment, then antiviral effect is achieved, but treatment effectiveness is limited to 40% and side effects are significant
Solution Approach 1:
The patent applies parameter changes by developing novel phosphonate compounds with modified chemical structures (Formulas I-IV) that target HCV NS5b polymerase differently from existing interferon-α and ribavirin treatments. This structural parameter change enables improved treatment effectiveness while reducing side effects through a new mechanism of action
Solution Approach 2:
The patent introduces phosphonate compounds as intermediary substances that specifically inhibit HCV NS5b polymerase. These compounds act as mediators between the treatment goal and the viral replication process, providing a more effective and tolerable treatment pathway compared to direct interferon-α and ribavirin administration
2Reliability
If novel phosphonate compounds are developed to target HCV NS5b polymerase, then treatment effectiveness is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antiviral treatment approach into specific molecular components - the phosphonate core structure and variable substituent groups (R1-R14). This segmentation allows systematic optimization of individual components to achieve effective HCV NS5b polymerase inhibition while managing development complexity through modular design
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters (substituent groups, molecular weight, lipophilicity) of the phosphonate compounds to optimize both effectiveness against HCV NS5b polymerase and tolerability profile, thereby improving treatment outcomes despite increased development complexity
Data Source
AI summary
A compound of Formula I, Formula II, Formula III, or Formula IV:or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.